[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1995

Pilot Study of Topical Calcitriol (1,25-Dihydroxyvitamin D3) for Treating Psoriasis in Children

Author Affiliations

Adrian Turner Boston

Vitamin D, Skin, and Bone Research Laboratory M-1013 Boston University School of Medicine 80 E Concord St Boston, MA 02118

Arch Dermatol. 1995;131(8):961-962. doi:10.1001/archderm.1995.01690200101025
Abstract

Based on evidence that calcitriol (1,25-dihydroxyvitamin D3) inhibits proliferation and induces differentiation of epidermal cells,1 this hormone and its analogues have been used successfully in the treatment of adult psoriasis.2,3 However, its clinical use in children has been limited because of concern that cutaneous absorption of this hormone may cause toxic effects. In this pilot study, we evaluated the therapeutic efficacy and safety of topical calcitriol in four children with psoriasis.

Subjects and Methods.  Two boys and two girls, whose ages ranged from 13 to 17 years, were enrolled in this double-blind intrapatient comparison after a 2-month washout period for the use of systemic antipsoriatic agents. The two boys were 175 and 160 cm tall and weighed 74.25 and 58.5 kg; the two girls were 152.5 and 142.5 cm tall and weighed 44 and 40 kg. All patients had at least 10% and up to 45% body

First Page Preview View Large
First page PDF preview
First page PDF preview
×